Arcutis (ARQT) director offloads 10,000 shares in 10b5-1 plan sale

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus sold shares under a pre-set trading plan. On February 2, 2026, he sold 10,000 shares of Arcutis common stock at a weighted average price of $25.0483 per share pursuant to a Rule 10b5-1 plan adopted on March 11, 2025. After this planned sale, he beneficially owns 59,744 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		10,000	D	$25.0483(2)	59,744	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Arcutis Biotherapeutics (ARQT) director Howard Welgus report on this Form 4?

Howard G. Welgus reported selling 10,000 shares of Arcutis common stock in a single reported transaction. The sale occurred on February 2, 2026 at a weighted average price of $25.0483 per share, and he now holds 59,744 shares beneficially and directly.

At what price did the Arcutis (ARQT) director sell his 10,000 shares?

The reported weighted average sale price was $25.0483 per share. The shares were actually sold in multiple trades, with individual prices ranging from $24.61 to $25.60, and the director has offered to provide detailed trade breakdowns upon request to regulators or shareholders.

How many Arcutis (ARQT) shares does director Howard Welgus own after this sale?

Following the reported Form 4 transaction, Howard G. Welgus beneficially owns 59,744 shares of Arcutis common stock. The filing shows these shares as directly held, meaning they are not reported as being owned through an intermediary entity such as a trust, partnership, or similar structure.

Was the Arcutis (ARQT) director’s 10,000-share sale part of a trading plan?

Yes. The sale was made under a Rule 10b5-1 trading plan adopted on March 11, 2025. This type of plan pre-schedules trades, helping insiders systematically sell shares over time according to predetermined instructions, with the plan running through May 29, 2026.

What does the weighted average price mean in this Arcutis (ARQT) Form 4?

The weighted average price of $25.0483 reflects multiple individual trades executed between $24.61 and $25.60. Instead of listing each separate trade, the filing aggregates them, and the reporting person has committed to supply the full price and share breakdown to interested parties upon request.

What is Howard Welgus’s role at Arcutis Biotherapeutics (ARQT)?

The Form 4 identifies Howard G. Welgus as a director of Arcutis Biotherapeutics, Inc. He is not listed as an officer or 10% owner in this filing. His relationship box is marked only for director status, which triggers ongoing Form 4 reporting obligations for his transactions.